TY - JOUR
T1 - Prescription patterns in patients with schizophrenia in Japan
T2 - First-quality indicator data from the survey of “Effectiveness of Guidelines for Dissemination and Education in psychiatric treatment (EGUIDE)” project
AU - Ichihashi, Kayo
AU - Hori, Hikaru
AU - Hasegawa, Naomi
AU - Yasuda, Yuka
AU - Yamamoto, Tomoya
AU - Tsuboi, Takashi
AU - Iwamoto, Kunihiro
AU - Kishimoto, Taishiro
AU - Horai, Tadasu
AU - Yamada, Hiroki
AU - Sugiyama, Nobuhiro
AU - Nakamura, Toshinori
AU - Tsujino, Naohisa
AU - Nemoto, Kiyotaka
AU - Oishi, Satoru
AU - Usami, Masahide
AU - Katsumoto, Eiichi
AU - Yamamori, Hidenaga
AU - Tomita, Hiroaki
AU - Suwa, Taro
AU - Furihata, Ryuji
AU - Inagaki, Takahiko
AU - Fujita, Junichi
AU - Onitsuka, Toshiaki
AU - Miura, Kenichiro
AU - Matsumoto, Junya
AU - Ohi, Kazutaka
AU - Matsui, Yuki
AU - Takaesu, Yoshikazu
AU - Hashimoto, Naoki
AU - Iga, Junichi
AU - Ogasawara, Kazuyoshi
AU - Yamada, Hisashi
AU - Watanabe, Koichiro
AU - Inada, Ken
AU - Hashimoto, Ryota
N1 - Funding Information:
This study was supported by the Japan Agency for Medical Research and Development (AMED) under grant number JP18dk0307060, JP19dk0307083, and JP20dk0307081, Health and Labor Sciences Research Grants (H29‐Seishin‐Ippan‐001, 19GC1201), the Japanese Society of Neuropsychopharmacology, and the Japanese Society of Mood Disorders. The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript
Publisher Copyright:
© 2020 The Authors. Neuropsychopharmacology Reports published by John Wiley & Sons Australia, Ltd on behalf of the Japanese Society of NeuropsychoPharmacology.
PY - 2020/9/1
Y1 - 2020/9/1
N2 - Background: Guideline for Pharmacological Therapy for Schizophrenia was published by the Japanese Society of Neuropsychopharmacology in 2015. “Effectiveness of Guidelines for Dissemination and Education in psychiatric treatment (EGUIDE)” project aimed to standardize medical practice using quality indicators (QIs) as indices to evaluate the quality of medical practice. In this study, we have reported the quality indicator values of prescription before the beginning of the guideline lectures in the EGUIDE project to ascertain the baseline status of treating patients with schizophrenia. Methods: A cross-sectional, retrospective case record survey was conducted, involving 1164 patients with schizophrenia at the time of discharge. We checked all types and dosage of psychotropic drugs. Results: Forty-three percent of patients had antipsychotic polypharmacy, and substantial concomitant medication was observed (antidepressants; 8%, mood stabilizers: 37%, anxiolytics or hypnotics: 68%). Conclusions: In the results obtained in this study, we plant to report changes in the effectiveness of education in the EGUIDE project near the future.
AB - Background: Guideline for Pharmacological Therapy for Schizophrenia was published by the Japanese Society of Neuropsychopharmacology in 2015. “Effectiveness of Guidelines for Dissemination and Education in psychiatric treatment (EGUIDE)” project aimed to standardize medical practice using quality indicators (QIs) as indices to evaluate the quality of medical practice. In this study, we have reported the quality indicator values of prescription before the beginning of the guideline lectures in the EGUIDE project to ascertain the baseline status of treating patients with schizophrenia. Methods: A cross-sectional, retrospective case record survey was conducted, involving 1164 patients with schizophrenia at the time of discharge. We checked all types and dosage of psychotropic drugs. Results: Forty-three percent of patients had antipsychotic polypharmacy, and substantial concomitant medication was observed (antidepressants; 8%, mood stabilizers: 37%, anxiolytics or hypnotics: 68%). Conclusions: In the results obtained in this study, we plant to report changes in the effectiveness of education in the EGUIDE project near the future.
KW - EGUIDE project
KW - antipsychotics
KW - guideline
KW - quality indicator
KW - schizophrenia
UR - http://www.scopus.com/inward/record.url?scp=85087287806&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85087287806&partnerID=8YFLogxK
U2 - 10.1002/npr2.12122
DO - 10.1002/npr2.12122
M3 - Article
C2 - 32602667
AN - SCOPUS:85087287806
VL - 40
SP - 281
EP - 286
JO - Neuropsychopharmacology Reports
JF - Neuropsychopharmacology Reports
SN - 2574-173X
IS - 3
ER -
